Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal.

Mémoire numérisé par la Division de la gestion de documents et des archives de l'Université de Montréal

Epidemiological studies implicate pesticide exposure as a possible etiologic factor in idiopathic Parkinson's Disease, which results from degeneration of nigrostriatal neurons, along with reduced levels of the neurotransmitter, dopamine. Behavioral and neurochemical analyses in C57BL6 mice were performed following a subchronic dosing regime with the organochlorine insecticide heptachlor or the pyrethroid deltamethrin. Results were compared to those induced by the established parkinsonian neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). At the end of the treatment period, mice were assessed for effects on behavior, as well as levels of striatal dopamine, nerve terminal respiration, and synaptosomal dopamine transport. The primary behavioral effect of deltamethrin was incoordination, while heptachlor caused hyperexcitability and increased locomotion. The major neurochemical effect observed for both compounds was upregulation of the presynaptic dopamine transporter (DAT) by 70% and 100% for deltamethrin and heptachlor, respectively. The insecticides exerted only modest effects on striatal levels of dopamine and its metabolite, dihydroxyphenylacetic acid. However, doses of heptachlor higher than those which caused induction of DAT (e.g. greater than or equal to 25 mg/kg), when administered subchronically, were found to cause convulsions in some animals and caused marked, dose-dependent depression of basal striatal tissue respiration rates. No synergism was observed between the effects of insecticides and MPTP. Enhanced transport was thought to be a compensatory effect from increased release of transmitters by the insecticides, <i>in vivo</i>. Striatal dopamine, GABA and glutamate nerve terminals were differentially sensitive to the releasing effects of heptachlor compared to cortical serotonin terminals, and responded in the following rank order of sensitivity: dopamine > GABA > glutamate > serotonin. Additional experiments to characterize the mechanism(s) by which cyclodienes facilitate release of neurotransmitters in synaptosomes demonstrated a lack of distinct Ca²⁺ component and no involvement of retrograde DAT activity, suggesting that released label was of vesicular origin, but did not require Ca²⁺. Insecticidal toxicants, such as organochlorines and pyrethroids, which augment dopamine release and increase the maximal rate of dopamine uptake, may inundate the cytosol of nigrostriatal neurons with high concentrations of free dopamine, which has been shown by other researchers to induce apoptosis and may thereby contribute to the development of Parkinson's disease. Funding for this work was provided under grant number HHHREP 94-01 by the Hawaii Heptachlor Foundation, a non-profit organization. The Hawaii Heptachlor Foundation may be contacted at the following address: Ocean View Center PH#3, 707 Richards St., Honolulu, HI 96813. / Ph. D.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21626号 / 医博第4432号 / 新制||医||1033(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 高橋 淳, 教授 宮本 享, 教授 林 康紀 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

To characterize corticostriatal projections from rodent sensorimotor cortex, the anterograde tracers biotinylated dextran amine (BDA) and fluororuby (FR) were injected into the whisker representations of the primary motor (MI) and somatosensory (SI) cortices. Reconstructions of labeled terminals and their beaded varicosities in the neostriatum and thalamus were analyzed quantitatively to determine the degree of labeled overlap in both of these subcortical structures. Corticostriatal projections from the vibrissal representation in MI were more extensive than corresponding projections from SI. Both cortical areas sent dense projections to the dorsolateral neostriatum, but the MI vibrissal representation also projected to regions located more rostrally and medially. Despite these differences, both MI and SI projected to overlapping parts of the dorsolateral neostriatum. Tracer injections in both cortical areas also produced dense anterograde and retrograde labeling in the medial sector of the posterior complex of the thalamus (POm). Because POm is somatotopically organized and has reciprocal connections with both SI and MI cortices, the amount of labeled overlap in POm was used to indicate whether the tracers were injected into corresponding whisker representations of MI and SI. We found that the proportion of labeled overlap in the neostriatum was highly correlated with the amount of labeled overlap in POm. These results indicate that the rodent neostriatum receives convergent projections from corresponding regions in MI and SI cortex. Furthermore, the thalamocortical projections of the POm indicate that it may modulate corticostriatal outputs from corresponding representations in MI and SI.

No description available.

Les problèmes de toxicomanie sont très communs chez les schizophrènes. L’administration chronique d’antipsychotiques pourrait être impliquée dans cette cooccurrence en induisant une hypersensibilisation du système dopaminergique. Précédemment, nous avons démontré chez le rat qu’un traitement continu (via une mini-pompe osmotique sous-cutanée), et non pas intermittent (via des injections journalières sous-cutanées), avec l’halopéridol a augmenté la capacité de l’amphétamine à potentialiser un comportement de recherche de récompense. Dans cette étude, nous avons étudié les effets d’un antipsychotique atypique soit l’olanzapine comparé à l’halopéridol. Un traitement continu avec l’halopéridol, et non pas l’olanzapine, a augmenté la capacité de l’amphétamine de potentialiser la poursuite d’une récompense conditionnée (lumière/son préalablement associés à l’eau). De plus, un traitement continu avec l’halopéridol a augmenté l’induction par l’amphétamine de l’activité locomotrice et l’expression d’ARNm pour le c-fos (marqueur fonctionnel d’activité cellulaire) dans le caudé-putamen. Donc, un traitement continu avec un antipsychotique typique, et non pas atypique, a augmenté les caractéristiques motivationnelles attribuées à un stimulus neutre. Ceci est potentiellement lié à au développement d’un état de sensibilisation comportementale aux effets de l’amphétamine et à une augmentation de la capacité de l’amphétamine de susciter la modulation de l’activité du caudé-putamen. Ainsi, un antipsychotique typique tel que l’halopéridol semble modifier les circuits de la récompense de façon à contribuer à des comportements caractérisés par une recherche et une consommation de drogues d’abus alors qu’un antipsychotique atypique tel que l’olanzapine aurait moins tendance à le faire. Nous suggérons que les antipsychotiques atypiques pourraient être une meilleure option chez les patients schizophrènes à risque d’avoir un trouble de consommation de drogues d’abus ou de toxicomanie. / Substance abuse problems are excessively common in schizophrenia. Chronic antipsychotic treatment might be involved in this co-morbidity by inducing supersensitivity in the brain’s dopamine system. We have shown previously in the rat that continuous (via osmotic subcutaneous minipump), but not intermittent (via daily subcutaneous injection), treatment with haloperidol potentiates the ability of amphetamine to enhance the pursuit of a conditioned reward. Here, we assessed the effects of the atypical antipsychotic olanzapine. Continuous treatment with haloperidol, but not with olanzapine, enhanced the capacity of amphetamine to potentiate the pursuit of a conditioned reward (a light-tone stimulus previously paired with water). In addition, continuous haloperidol treatment augmented both amphetamine-induced locomotion and striatal c-fos mRNA expression. These effects were either absent or less pronounced following continuous olanzapine treatment. Thus, continuous treatment with a typical, but not with an atypical, antipsychotic enhanced the incentive motivational properties of a reward cue, and this was potentially linked to the development of behavioural supersensitivity to amphetamine and to a greater ability of amphetamine to engage the caudate-putamen. Thus, a typical antipsychotic like haloperidol appears to modify the brain’s reward system in ways that could contribute to drug-seeking and drug-taking behaviour, but an atypical antipsychotic like olanzapine might be less likely to do so. We suggest that atypical antipsychotics might be a preferential option in schizophrenic patients at risk for drug abuse or addiction.

Les médicaments antipsychotiques améliorent les symptômes de la schizophrénie, mais peuvent perdre leur efficacité à long terme en sensibilisant le système dopaminergique. Les mécanismes sous-tendant cette sensibilisation ne sont pas connus. Le neuropeptide neurotensine module le système dopaminergique et est régulé par les antipsychotiques dans le noyau accumbens. Dans cette région, la neurotensine peut avoir des effets anti- et pro-dopaminergiques via les récepteurs NTS1. Nous avions pour hypothèse que la neurotensine du noyau accumbens module l’expression de la sensibilisation dopaminergique induite par les antipsychotiques. Ainsi, nous avons traité par intermittence ou continuellement des rats à l’antipsychotique halopéridol. Seule l’administration continue sensibilise le système dopaminergique et donc sensibilise aux effets locomoteurs de l’amphétamine. Des microinjections de neurotensine dans le noyau accumbens ont diminué l’hyperlocomotion induite par l’amphétamine chez les rats témoins et ceux traités par intermittence aux antipsychotiques. Au contraire, la sensibilisation dopaminergique induite par un traitement continu serait liée à une augmentation des effets pro-dopaminergiques de la neurotensine. Ceci est indépendant d’un changement de densité des récepteurs NTS1 dans le noyau accumbens. Un traitement intermittent n’a pas d’effet sur cette mesure également. De plus, autant un traitement antipsychotique continu qu’intermittent augmentent la transcription de proneurotensine. Donc, seule l’altération de la fonction de la neurotensine du noyau accumbens corrèle avec la sensibilisation dopaminergique. En parallèle, dans le caudé-putamen, un traitement continu augmente la transcription de proneurotensine et un traitement intermittent augmente la densité des récepteurs NTS1. En somme, la neurotensine du noyau accumbens module la sensibilisation dopaminergique induite par les antipsychotiques. / Antipsychotic medications improve schizophrenia symptoms, but they can also sensitize the dopamine system over time, consequently leading to impaired treatment efficacy. The mechanisms underlying antipsychotic-evoked dopamine supersensitivity are not known. The neuropeptide neurotensin regulates the dopamine system and can be modulated by antipsychotics, particularly in the nucleus accumbens. In this area, neurotensin has both anti- and pro-dopaminergic effects via an interaction with NTS1 receptors. In the present study, we hypothesized that neurotensin in the nucleus accumbens can modulate the expression of dopamine supersensitivity-evoked by an antipsychotic treatment. We treated rats with the antipsychotic haloperidol administered either intermittently or continuously. Continuous, but not intermittent, haloperidol treatment induces dopamine supersensitivity as shown by an increased locomotor activity induced by amphetamine. Microinjections of neurotensin in the nucleus accumbens diminish amphetamine-induced locomotion in control and intermittently antipsychotic-treated rats. Dopamine supersensitivity-evoked by a continuous antipsychotic treatment is linked to a potential enhancement of the pro-dopaminergic effects of neurotensin. This is not caused by any change in NTS1 receptor levels in the nucleus accumbens. An intermittent treatment did not alter NTS1 receptor levels as well in this area. Also, both continuous and intermittent treatment increased neurotensin transcription in the nucleus accumbens. Thus, only neurotensin altered function correlates with dopamine supersensitivity. In the caudate-putamen, continuous antipsychotic treatment increased neurotensin transcription, whereas intermittent treatment increased NTS1 receptor levels. In summary, neurotensin in the nucleus accumbens can modulate the expression of dopamine supersensitivity-evoked by antipsychotics.

Les problèmes de toxicomanie sont très communs chez les schizophrènes. L’administration chronique d’antipsychotiques pourrait être impliquée dans cette cooccurrence en induisant une hypersensibilisation du système dopaminergique. Précédemment, nous avons démontré chez le rat qu’un traitement continu (via une mini-pompe osmotique sous-cutanée), et non pas intermittent (via des injections journalières sous-cutanées), avec l’halopéridol a augmenté la capacité de l’amphétamine à potentialiser un comportement de recherche de récompense. Dans cette étude, nous avons étudié les effets d’un antipsychotique atypique soit l’olanzapine comparé à l’halopéridol. Un traitement continu avec l’halopéridol, et non pas l’olanzapine, a augmenté la capacité de l’amphétamine de potentialiser la poursuite d’une récompense conditionnée (lumière/son préalablement associés à l’eau). De plus, un traitement continu avec l’halopéridol a augmenté l’induction par l’amphétamine de l’activité locomotrice et l’expression d’ARNm pour le c-fos (marqueur fonctionnel d’activité cellulaire) dans le caudé-putamen. Donc, un traitement continu avec un antipsychotique typique, et non pas atypique, a augmenté les caractéristiques motivationnelles attribuées à un stimulus neutre. Ceci est potentiellement lié à au développement d’un état de sensibilisation comportementale aux effets de l’amphétamine et à une augmentation de la capacité de l’amphétamine de susciter la modulation de l’activité du caudé-putamen. Ainsi, un antipsychotique typique tel que l’halopéridol semble modifier les circuits de la récompense de façon à contribuer à des comportements caractérisés par une recherche et une consommation de drogues d’abus alors qu’un antipsychotique atypique tel que l’olanzapine aurait moins tendance à le faire. Nous suggérons que les antipsychotiques atypiques pourraient être une meilleure option chez les patients schizophrènes à risque d’avoir un trouble de consommation de drogues d’abus ou de toxicomanie. / Substance abuse problems are excessively common in schizophrenia. Chronic antipsychotic treatment might be involved in this co-morbidity by inducing supersensitivity in the brain’s dopamine system. We have shown previously in the rat that continuous (via osmotic subcutaneous minipump), but not intermittent (via daily subcutaneous injection), treatment with haloperidol potentiates the ability of amphetamine to enhance the pursuit of a conditioned reward. Here, we assessed the effects of the atypical antipsychotic olanzapine. Continuous treatment with haloperidol, but not with olanzapine, enhanced the capacity of amphetamine to potentiate the pursuit of a conditioned reward (a light-tone stimulus previously paired with water). In addition, continuous haloperidol treatment augmented both amphetamine-induced locomotion and striatal c-fos mRNA expression. These effects were either absent or less pronounced following continuous olanzapine treatment. Thus, continuous treatment with a typical, but not with an atypical, antipsychotic enhanced the incentive motivational properties of a reward cue, and this was potentially linked to the development of behavioural supersensitivity to amphetamine and to a greater ability of amphetamine to engage the caudate-putamen. Thus, a typical antipsychotic like haloperidol appears to modify the brain’s reward system in ways that could contribute to drug-seeking and drug-taking behaviour, but an atypical antipsychotic like olanzapine might be less likely to do so. We suggest that atypical antipsychotics might be a preferential option in schizophrenic patients at risk for drug abuse or addiction.

Decision-making is comprised of an incredibly varied set of behaviours. However, all vertebrates tend to repeat previously rewarding actions and avoid those that have led to loss, behaviours known collectively as the win-stay, lose-shift strategy. This response strategy is supported by the sensorimotor striatum and nucleus accumbens, structures also implicated in spatial processing and the integration of sensory information in order to guide motor action. Therefore, choices may be represented as spatial-motor actions whose value is determined by the rewards and punishments associated with that action. In this dissertation I demonstrate that the location of choices relative to previous rewards and punishments, rather than their identities, determines their value. Chapters 2 and 4 demonstrate that the location of rewards and punishments drives future decisions to win-stay or lose-shift towards that location. Even when choices differ in colour or shape, choice value is determined by location, not visual identity. Chapter 3 compares decision-making when two, six, twelve, or eighteen choices are present, finding that the value of a win or loss is not tied to a single location, but is distributed throughout the choice environment. Finally, Chapter 5 provides anatomical support for the spatial-motor basis of choice. Specifically, win-stay responses are associated with greater oscillatory activity than win-shift responses in the motor cortex corresponding to the hand used to make a choice, whereas lose-shift responses are accompanied by greater activation of frontal systems compared to lose-stay responses. The win-stay and lose-shift behaviours activate structures known to project to different regions of the striatum. Overall, this dissertation provides behavioural evidence that choice location, not visual identity, determines choice value. / Thesis / Doctor of Philosophy (PhD)